As of 29 Oct 2026, Omabit has raised $2M across 1 verified round on record; latest: $2 million seed round led by Bright Ventures, announced 26 Oct 2026.
A company developing AI to support scientific decision-making
omabit.comNew YorkAI
13 sources
Citybiz's roundup listed a $5M seed round, but Omabit's release states $2 million; the company release controls.
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Seed | $2M | 2026-10-26 | Bright Ventures | No recent discussion |
13 sources [ VERIFIED · CORRECTED ] read against 4 of 13 sources
Citybiz's roundup listed a $5M seed round, but Omabit's release states $2 million; the company release controls. [ BUILT WITH ]·[ SEARCH ]found on a watched publisher·[ SCRAPE ]13 pages read: omabit.com, businesswire.com, citybiz.co·[ JSON ]round read into a schema, with the sentence that states it·[ VERIFY ]correctedchecked against 4 of 13 sources·[ BRANDING ]logo and colour from the homepage·[ AGENT ]company research by the Firecrawl agent | ||||
Omabit targets a costly bottleneck in drug development by bringing fragmented genomic, clinical, and published evidence together so life-science teams can investigate findings and plan trials faster; the company says analyses that typically take three months can take one day, while only 29% of Phase 2 drugs reach Phase 3. The $2 million seed led by Bright Ventures will fund platform development and expand scientific and engineering capacity, betting that traceable AI analyses can become part of clinical-development and regulatory workflows.
Checked against 8 sources yesterday
Also named as backers in company research: StartX